Adding the glucagon pathway is the feature researchers believe may give retatrutide an edge on weight loss though only further study will confirm how it compares head-to-head over the long term
These medications mimic the activity of natural hormone glucagon-like peptide-1 (GLP-1) receptors located in the pancreas, brain, and gut to slow gastric emptying, increase insulin secretion, reduce appetite, and improve blood glucose levels
The FDA-approved GLP-1 medications come in injectable pens with precise dosing, whereas compounded GLP-1 drugs typically come in a vial with a syringe that can offer more flexibility for microdosing, but also opens up the chance for taking too much or too little medication
The Bridge program is slated to run until the end of 2027, prompting providers to raise concerns about what will happen if the government does not extend it as people typically regain the weight they lost after stopping a GLP-1
Many BCBS plans require evidence of previous weight loss attempts before authorizing semaglutide, effectively creating gatekeeping barriers that delay treatment initiation
